micro-community-banner
 
  • Saved

Enhancing Patient Outcomes in gMG Through Shared Decision-Making

Shared decision-making (SDM) is a patient-centered healthcare model fostering collaboration between patients, caregivers, and providers. For patients with generalized myasthenia gravis (gMG), SDM helps navigate complex treatment decisions while aligning care with individual preferences and values. This is particularly critical in gMG due to its diverse symptom burden and evolving therapeutic landscape.

Studies show that SDM improves decision quality, enhances patient autonomy, and reduces decisional regret. Tools like the SHARE approach guide providers through key steps: engaging patients, comparing treatment options, assessing values, making joint decisions, and evaluating outcomes.

Despite its benefits, barriers such as time constraints, inadequate patient education, and limited provider training often hinder SDM adoption. To overcome these challenges, interventions like decision aids and patient activation strategies have shown promise. While no single approach has been proven superior, training programs like the SDM-N scale can enhance provider competency and improve care quality.

In gMG management, SDM also promotes effective care coordination by facilitating communication between specialists, such as neurologists, and generalists, including PCPs, NPs, and PAs. This collaboration ensures that all members of the care team are aligned on treatment goals, enabling comprehensive, patient-centered care. By embracing SDM, providers can empower gMG patients to actively participate in their treatment, fostering better outcomes and stronger patient-provider relationships.

How do you integrate SDM into your gMG treatment planning? What strategies or frameworks have you found most effective in supporting patient involvement?

  • April 12, 2025
    I try to integrate shared decision making in all of my patient appointments. I probably incorporate it most of all when discussing medication choices. I will typically go over multiple options for medication choices with the patient in great detail. We will go over the pros and cons of each and discuss which would be best in a collaborative way. I find this gets the patients buy in and typically promotes compliance with the patient.
  • April 10, 2025
    I integreate SDM in gMG treatment planning by really educating my patients about the disease and how treatments work. Some strateggies that I have found effective is not using jargon when talking about treatments and their potential side effects.
  • April 09, 2025
    Sometimes patients also need psychiatrists or counselors as part of the team as this disease can have emotional implications as well with adjusting to diagnosis and treatments.
  • April 09, 2025
    Shred decision making approach is helpful in many ways. It helps to make a decision in a different different areas of the medical problems patient may have it. . Patient get help for their the pulmonary symptoms from Pulmonologist, , generalized fatigue, cognitive issues - from neurolologist, , and during the crisis- they can have lot in making appropriate decision for the patient.
  • March 20, 2025
    I always take shared decision-making approach in managing patients with gMG, to help them navigate the complex treatment options. I strongly believe this patient-centric strategy can allow them to be more actively engaged in treatment plan, enhance medical compliance and clinical outcomes.
  • February 28, 2025
    I don’t have many patients with MG. If I did, I would refer major management decisions to the neurologist.
Profile Image
  • Saved

American Academy of Neurology Annual Meeting

The American Academy of Neurology (AAN) 2025 Annual Meeting features more than 190 educational and scientific programs and 3,200 abstracts presented over five days. Being held at the San Diego Convention Center and online, the meeting highlights the latest research and real-world evidence on the prevention, diagnosis, and treatment of the full spectrum of neurological diseases and conditions, including myasthenia gravis (MG), dementia, stroke, and sleep disorders.

Above, we summarize some presentations that caught our eye at the conference this week. We will follow this up with a postconference wrap-up report. Stay tuned.

  • Saved

American Academy of Neurology Annual Meeting

The 2025 American Academy of Neurology (AAN) Annual Meeting continues to impress and educate its attendees through day 3. The meeting features more than 190 educational and scientific programs and 3,200 abstracts presented over five days. Held at the San Diego Convention Center and online, the meeting covers the full spectrum of neurological conditions, including Alzheimer disease, stroke, concussion, epilepsy, Parkinson disease, multiple sclerosis, headache, migraine, and myasthenia gravis (MG).

Above, we summarize key research and presentations that caught our attention thus far. We will follow this up with continued coverage and a postconference wrap-up report. Stay tuned.

  • Saved

American Academy of Neurology Annual Meeting

Held at the San Diego Convention Center and online, the 2025 American Academy of Neurology (AAN) Annual Meeting is underway and features more than 190 educational and scientific programs. The five-day meeting hosts thousands of neurologists and neuroscientists who unpack the latest research on the prevention, diagnosis, and treatment of Alzheimer disease, stroke, concussion, epilepsy, Parkinson disease, multiple sclerosis, headache, migraine, myasthenia gravis (MG), and more.

Above, we summarize key research and presentations that caught our attention at the conference. We will follow this up with continued coverage and a postconference wrap-up report soon.

  • Saved

Peripheral Nervous System Complications after COVID-19 Vaccination - PubMed

Peripheral Nervous System Complications after COVID-19 Vaccination - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/40152570/

While vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains crucial, neurological complications have been detected following the coronavirus disease 2019 (COVID-19) vaccination. The neurological complications of COVID-19 vaccination...

 

Peripheral nervous system (PNS) complications after COVID-19 vaccination include polyneuropathy, neuropathies, and myasthenia gravis; diagnosis and management are crucial, though vaccine benefits still outweigh risks.